Table 1.
Patients’ characteristics at baseline and at 1‐year confirmatory biopsy.
| Characteristic | Baseline | Confirmatory biopsy (1‐year surveillance) | P * |
|---|---|---|---|
| Total cohort (n = 111) | Total cohort (n = 111) | ||
| Median (IQR) | |||
| Age, years | 66 (60–70) | 67 (61–71) | <0.001 |
| PSA level, ng/mL | 6.8 (5.1–9.1) | 6.9 (5.2–9.4) | 0.352 |
| Prostate volume, mL | 42 (30–56) | 41 (31–55) | 0.695 |
| PSA density, ng/mL/mL | 0.17 (0.11–0.25) | 0.15 (0.12–0.27) | 0.864 |
| N (%) | |||
| Clinical stage | |||
| T1c | 85 (77) | 80 (72) | 0.665 |
| T2a | 22 (20) | 25 (23) | |
| T2b | 2 (2) | 4 (4) | |
| T2c | 1 (1) | 2 (2) | |
| T3a | 1 (1) | 0 (0) | |
| TRUS findings | |||
| Benign | 93 (84) | 91 (82) | 0.774 |
| Suspected | 18 (16) | 20 (18) | |
| Number of positive diagnostic cores | |||
| 1 | 46 (41) | N/A | N/A |
| 2 | 36 (32) | N/A | |
| 3 | 19 (17) | N/A | |
| 4 | 7 (6) | N/A | |
| 5 | 2 (2) | N/A | |
| 6 | 1 (1) | N/A | |
| PI‐RADS score of MRI | |||
| 1–2 | 52 (47) | 48 (43) | 0.303 |
| 3 | 15 (14) | 13 (12) | |
| 4 | 35 (32) | 40 (36) | |
| 5 | 9 (8) | 10 (9) | |
| PRECISE score of MRI | |||
| 1–2 | N/A | 14 (13) | N/A |
| 3 | N/A | 80 (72) | |
| 4–5 | N/A | 17 (15) | |
| Time between MRIs, months, median (IQR) | N/A | 10 (9–13) | N/A |
| Overall ISUP Grade at biopsy, n (%) | |||
| No PCa | N/A | 31 (28) | N/A |
| G 1 | 111 (100) | 45 (41) | |
| G 2 | N/A | 18 (16) | |
| G 2 with CR and/or IDC | N/A | 12 (11) | |
| G 3 | N/A | 5 (5) | |
| G 4–5 | N/A | 0 (0) | |
CR, cribriform growth pattern; G, grade; IDC, intraductal carcinoma; ISUP, International Society of Urological Pathology; IQR, interquartile range; N/A, not applicable; PCa, prostate cancer; PI‐RADS, Prostate Imaging‐Reporting and Data System; PRECISE, Prostate Cancer Radiological Estimation of Change in Sequential Evaluation.
*
P values calculated based on the comparison between the baseline and confirmatory characteristics for the total cohort.